Similar companies
Income Statement (NONE)
| Q4 '25 | QoQ | |
|---|---|---|
| Revenue | 17.6B | 5.4% |
| Gross Profit | 12.3B | 1.6% |
| Cost of Revenue | 5.27B | 26.4% |
| Operating expense | 8.6B | 3.8% |
| Net Income | -1.65B | 146.5% |
| EBITDA | -930M | 116.5% |
Balance Sheet (NONE)
| Q4 '25 | QoQ | |
|---|---|---|
| Total Equity | 93.1B | 0.3% |
| Shares Outstanding | 5.69B | 0.5% |
Cash Flow (NONE)
| Q4 '25 | QoQ |
|---|
EPS
Financial Highlights for Pfizer in Q4 '25
Pfizer reported a revenue of 17.6B, which is a 5.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 12.3B, marking a -1.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 5.27B, a 26.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 8.6B, showing a -3.8% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -1.65B, showing a -146.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -930M, showing a -116.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Pfizer faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures. A decline in EBITDA signals potential operational challenges or increased costs.
